ITRM20020277A1 - Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni. - Google Patents

Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.

Info

Publication number
ITRM20020277A1
ITRM20020277A1 IT2002RM000277A ITRM20020277A ITRM20020277A1 IT RM20020277 A1 ITRM20020277 A1 IT RM20020277A1 IT 2002RM000277 A IT2002RM000277 A IT 2002RM000277A IT RM20020277 A ITRM20020277 A IT RM20020277A IT RM20020277 A1 ITRM20020277 A1 IT RM20020277A1
Authority
IT
Italy
Prior art keywords
preparation
growth factor
type
placentar
muteine
Prior art date
Application number
IT2002RM000277A
Other languages
English (en)
Italian (it)
Inventor
Giuseppe Salvia
Ettore Conti
Domenico Maglione
Marina Tucci
Mauro Battisti
Alberto Mion
Original Assignee
Geymonat Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11456311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITRM20020277(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geymonat Spa filed Critical Geymonat Spa
Priority to IT2002RM000277A priority Critical patent/ITRM20020277A1/it
Publication of ITRM20020277A0 publication Critical patent/ITRM20020277A0/it
Priority to PCT/IT2003/000296 priority patent/WO2003097688A2/en
Priority to CA2485587A priority patent/CA2485587C/en
Priority to KR1020047018601A priority patent/KR101022934B1/ko
Priority to BR0309966-0A priority patent/BR0309966A/pt
Priority to PL372492A priority patent/PL209955B1/pl
Priority to AU2003234066A priority patent/AU2003234066B2/en
Priority to US10/514,707 priority patent/US7314734B2/en
Priority to JP2004506360A priority patent/JP4230450B2/ja
Priority to CNB038112043A priority patent/CN1323167C/zh
Priority to DE60334986T priority patent/DE60334986D1/de
Priority to ES03727958T priority patent/ES2356360T3/es
Priority to EP03727958A priority patent/EP1506295B1/en
Priority to AT03727958T priority patent/ATE488590T1/de
Priority to RU2004137000/13A priority patent/RU2344172C2/ru
Priority to MXPA04011405A priority patent/MXPA04011405A/es
Priority to DK03727958.5T priority patent/DK1506295T3/da
Priority to PT03727958T priority patent/PT1506295E/pt
Publication of ITRM20020277A1 publication Critical patent/ITRM20020277A1/it
Priority to ZA2004/09943A priority patent/ZA200409943B/en
Priority to HRP20041178AA priority patent/HRP20041178B1/hr
Priority to HK05111674A priority patent/HK1079549A1/xx
Priority to US11/967,469 priority patent/US7807178B2/en
Priority to CY20111100200T priority patent/CY1111431T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT2002RM000277A 2002-05-17 2002-05-17 Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni. ITRM20020277A1 (it)

Priority Applications (23)

Application Number Priority Date Filing Date Title
IT2002RM000277A ITRM20020277A1 (it) 2002-05-17 2002-05-17 Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
DK03727958.5T DK1506295T3 (da) 2002-05-17 2003-05-19 Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf
PT03727958T PT1506295E (pt) 2002-05-17 2003-05-19 Muteínas do factor de crescimento placentário do tipo 1, processo de preparação e sua aplicação
CNB038112043A CN1323167C (zh) 2002-05-17 2003-05-19 1型胎盘生长因子的突变蛋白及其制备方法和应用
EP03727958A EP1506295B1 (en) 2002-05-17 2003-05-19 Muteins of placental growth factor type 1, preparation method and application thereof
KR1020047018601A KR101022934B1 (ko) 2002-05-17 2003-05-19 태반성장인자 타입 1 뮤테인의 제조방법 및 이의 사용방법
BR0309966-0A BR0309966A (pt) 2002-05-17 2003-05-19 Muteìnas de fator de crescimento placentário tipo 1, método de preparação e seus usos
PL372492A PL209955B1 (pl) 2002-05-17 2003-05-19 Zmutowane białko łożyskowego czynnika wzrostu typu 1, sekwencja nukleotydowa zawierająca DNA kodujące zmutowane białko, system ekspresji, komórka gospodarza , sposób wytwarzania sekwencji nukleotydowej, sposób wytwarzania i ekstrakcji zmutowanego białka, zmutowane białko do zastosowania w sposobie leczenia, przeciwciało zdolne do rozpoznawania zmutowanego białka, kompozycja farmaceutyczna, kompozycja kosmetyczna i sposób wytwarzania kompozycji farmaceutycznej lub kosmetycznej
AU2003234066A AU2003234066B2 (en) 2002-05-17 2003-05-19 Muteins of placental growth factor type 1, preparation method and application thereof
US10/514,707 US7314734B2 (en) 2002-05-17 2003-05-19 Muteins of placental growth factor type 1, preparation method and application thereof
JP2004506360A JP4230450B2 (ja) 2002-05-17 2003-05-19 胎盤成長因子１型の変異タンパク質、その調製方法及び応用
PCT/IT2003/000296 WO2003097688A2 (en) 2002-05-17 2003-05-19 Muteins of placental growth factor type 1, preparation method and application thereof
DE60334986T DE60334986D1 (de) 2002-05-17 2003-05-19 Muteine des placental growth factor type 1, herstellungsmethode und anwendung davon
ES03727958T ES2356360T3 (es) 2002-05-17 2003-05-19 Muteínas del factor de crecimiento placentario de tipo 1, método de preparación y aplicación de las mismas.
CA2485587A CA2485587C (en) 2002-05-17 2003-05-19 Muteins of placental growth factor type 1, preparation method and application thereof
AT03727958T ATE488590T1 (de) 2002-05-17 2003-05-19 Muteine des placental growth factor type 1, herstellungsmethode und anwendung davon
RU2004137000/13A RU2344172C2 (ru) 2002-05-17 2003-05-19 Мутеины плацентарного фактора роста 1 типа, способ их получения и применение
MXPA04011405A MXPA04011405A (es) 2002-05-17 2003-05-19 Muteinas del factor de crecimiento placentario tipo 1, metodo de preparacion y aplicacion.
ZA2004/09943A ZA200409943B (en) 2002-05-17 2004-12-08 Muteins of placental growth factor type 1,preparation method and application thereof
HRP20041178AA HRP20041178B1 (hr) 2002-05-17 2004-12-10 Muteini placentalnog faktora rasta tipa 1, metode njihove pripreme i primjene
HK05111674A HK1079549A1 (en) 2002-05-17 2005-12-19 Muteins of placental growth factor type 1, preparation method and application thereof
US11/967,469 US7807178B2 (en) 2002-05-17 2007-12-31 Muteins of placental growth factor type I, preparation method and application thereof
CY20111100200T CY1111431T1 (el) 2002-05-17 2011-02-16 Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002RM000277A ITRM20020277A1 (it) 2002-05-17 2002-05-17 Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.

Publications (2)

Publication Number Publication Date
ITRM20020277A0 ITRM20020277A0 (it) 2002-05-17
ITRM20020277A1 true ITRM20020277A1 (it) 2003-11-17

Family

ID=11456311

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002RM000277A ITRM20020277A1 (it) 2002-05-17 2002-05-17 Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.

Country Status (22)

Country Link
US (1) US7314734B2 (zh)
EP (1) EP1506295B1 (zh)
JP (1) JP4230450B2 (zh)
KR (1) KR101022934B1 (zh)
CN (1) CN1323167C (zh)
AT (1) ATE488590T1 (zh)
AU (1) AU2003234066B2 (zh)
BR (1) BR0309966A (zh)
CA (1) CA2485587C (zh)
CY (1) CY1111431T1 (zh)
DE (1) DE60334986D1 (zh)
DK (1) DK1506295T3 (zh)
ES (1) ES2356360T3 (zh)
HK (1) HK1079549A1 (zh)
HR (1) HRP20041178B1 (zh)
IT (1) ITRM20020277A1 (zh)
MX (1) MXPA04011405A (zh)
PL (1) PL209955B1 (zh)
PT (1) PT1506295E (zh)
RU (1) RU2344172C2 (zh)
WO (1) WO2003097688A2 (zh)
ZA (1) ZA200409943B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046722A2 (de) 2002-11-16 2004-06-03 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
JP2009100680A (ja) * 2007-10-23 2009-05-14 Univ Nagoya ヒト全身性強皮症動物モデルの作製方法、ヒト全身性強皮症動物モデル及びその用途
CN101918834B (zh) 2008-01-07 2014-05-28 奥索临床诊断有限公司 用于同时分析能够彼此络合的蛋白质的校准物/对照物
CN101918839A (zh) * 2008-01-07 2010-12-15 奥索临床诊断有限公司 sFlt-1:血管生成因子络合物的测定
EP2295449A1 (en) * 2009-09-09 2011-03-16 Dompe PHA.R.MA S.p.A. PLGF-1 in homodimeric form
CN103087153B (zh) 2011-10-28 2015-05-06 上海市第一人民医院 一类新的抑制新生血管的小肽及其应用
AU2014273027B2 (en) 2013-05-31 2019-07-04 Cobiores Nv Human PlGF-2 for the prevention or treatment of heart failure
CN109134650A (zh) * 2018-09-10 2019-01-04 宁波奥丞生物科技有限公司 抗人plgf单克隆抗体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
DE69229454T2 (de) * 1991-03-28 2000-01-05 Merck & Co Inc Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
DE19748734A1 (de) * 1997-11-05 1999-05-06 Biotechnolog Forschung Gmbh Verfahren zur Gewinnung von biologisch aktiven Dimeren von rekombinanten humanen Wachstumsfaktoren aus der Cystein-Knoten-Familie sowie Verwendung der gewonnenen Dimere
KR20020092779A (ko) * 1999-06-03 2002-12-12 휴먼 게놈 사이언시즈, 인코포레이티드 혈관형성 단백질 및 이의 용도
AU2001265953B2 (en) * 2000-05-12 2005-09-29 D. Collen Research Foundation Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage

Also Published As

Publication number Publication date
DK1506295T3 (da) 2011-03-07
ITRM20020277A0 (it) 2002-05-17
JP4230450B2 (ja) 2009-02-25
EP1506295A2 (en) 2005-02-16
PL372492A1 (en) 2005-07-25
US20050176634A1 (en) 2005-08-11
KR20040111639A (ko) 2004-12-31
EP1506295B1 (en) 2010-11-17
WO2003097688A9 (en) 2005-01-06
ATE488590T1 (de) 2010-12-15
KR101022934B1 (ko) 2011-03-16
CA2485587C (en) 2012-08-21
HK1079549A1 (en) 2006-04-07
US7314734B2 (en) 2008-01-01
AU2003234066B2 (en) 2009-04-23
JP2006508637A (ja) 2006-03-16
HRP20041178A2 (en) 2005-10-31
RU2004137000A (ru) 2005-06-10
BR0309966A (pt) 2005-03-01
PT1506295E (pt) 2011-02-23
RU2344172C2 (ru) 2009-01-20
PL209955B1 (pl) 2011-11-30
DE60334986D1 (de) 2010-12-30
HRP20041178B1 (hr) 2013-11-22
MXPA04011405A (es) 2005-02-14
WO2003097688A3 (en) 2004-02-26
CN1323167C (zh) 2007-06-27
WO2003097688A2 (en) 2003-11-27
ES2356360T3 (es) 2011-04-07
AU2003234066A1 (en) 2003-12-02
CY1111431T1 (el) 2015-08-05
CA2485587A1 (en) 2003-11-27
CN1653177A (zh) 2005-08-10
ZA200409943B (en) 2005-09-28

Similar Documents

Publication Publication Date Title
HK1079549A1 (en) Muteins of placental growth factor type 1, preparation method and application thereof
EA200901459A1 (ru) Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства
RU2009100884A (ru) Пептидные фрагменты для индукции синтеза белков внеклеточного матрикса
BRPI0511421A (pt) composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
DE602004023725D1 (de) Muteine von tränen-lipocalin
DE602006020898D1 (de) Peptide zur förderung des haarwachstums und zur verbesserung von falten und kosmetische zusammensetzungen, die diese enthalten
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
HUP0302026A2 (hu) Növekedési hormon szekrécióját fokozó triptofánszármazékok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
EP1614675A3 (en) Amino acids with affinity for the alpha-2-delta protein
NO331277B1 (no) Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
CN116802190A (zh) 特异于转铁蛋白受体1（TfR1）的双环肽配体
NO20010940L (no) TAN-1057 derivater
NO20055754L (no) Kolkisosidanaloger
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes
ATE408619T1 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
ATE291587T1 (de) Somatostatin analoge und deren verwendung zur behandlung von krebs
DE602004031886D1 (de) Auf öligen substanzen basierte körperreinigungzubereitung
JP2015051953A (ja) 血管弛緩作用を有するペプチド及び血管弛緩剤
DE50310131D1 (de) Peptide mit hohem cysteingehalt
DE50212538D1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten